These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2033771)

  • 21. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
    Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
    Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
    Gourevitch MN; Hartel D; Selwyn PA; Schoenbaum EE; Klein RS
    AIDS; 1999 Oct; 13(15):2069-74. PubMed ID: 10546859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
    Salpeter SR
    West J Med; 1993 Nov; 159(5):560-4. PubMed ID: 8279152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should young adults with a positive tuberculin test take isoniazid?
    Taylor WC; Aronson MD; Delbanco TL
    Ann Intern Med; 1981 Jun; 94(6):808-13. PubMed ID: 7235424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion.
    Camins BC; Bock N; Watkins DL; Blumberg HM
    JAMA; 1996 Apr; 275(13):1013-5. PubMed ID: 8596233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K; Alaei A; Mansouri D
    East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventive therapy of tuberculous infection.
    Am Rev Respir Dis; 1974 Sep; 110(3):371-4. PubMed ID: 4415195
    [No Abstract]   [Full Text] [Related]  

  • 30. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.
    Bark CM; Morrison CS; Salata RA; Byamugisha JK; Katalemwa NH; Mugerwa RD; Mukasa JB; Musoke RN; Nankya-Mutyoba J; Rwambuya S; Walker CJ; Johnson JL
    Int J Tuberc Lung Dis; 2010 Dec; 14(12):1647-9. PubMed ID: 21144254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculin sensitivity testing and treatment of latent tuberculosis remains effective for tuberculosis control in human immunodeficiency virus-infected patients in Hong Kong.
    Lin AW; Chan KC; Chan WK; Wong KH
    Hong Kong Med J; 2013 Oct; 19(5):386-92. PubMed ID: 23926172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy.
    Daley CL; Hahn JA; Moss AR; Hopewell PC; Schecter GF
    Am J Respir Crit Care Med; 1998 Jan; 157(1):19-22. PubMed ID: 9445273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid prophylaxis re-examined.
    Noble J
    N Engl J Med; 1971 Sep; 285(12):687-9. PubMed ID: 5563483
    [No Abstract]   [Full Text] [Related]  

  • 34. Preventive therapy of tuberculosis.
    Brummer DL
    Annu Rev Med; 1974; 25():115-22. PubMed ID: 4596225
    [No Abstract]   [Full Text] [Related]  

  • 35. Tuberculosis chemoprophylaxis.
    Salpeter S
    West J Med; 1992 Oct; 157(4):421-4. PubMed ID: 1462535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring preventive therapy patients for liver disease as well as compliance.
    Reichman LB
    Chest; 1975 Aug; 68(2):178-80. PubMed ID: 1149546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
    Sadaphal P; Astemborski J; Graham NM; Sheely L; Bonds M; Madison A; Vlahov D; Thomas DL; Sterling TR
    Clin Infect Dis; 2001 Nov; 33(10):1687-91. PubMed ID: 11641824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
    Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons.
    Stead WW; To T; Harrison RW; Abraham JH
    Ann Intern Med; 1987 Dec; 107(6):843-5. PubMed ID: 3688677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users.
    Graham NM; Nelson KE; Solomon L; Bonds M; Rizzo RT; Scavotto J; Astemborski J; Vlahov D
    JAMA; 1992 Jan; 267(3):369-73. PubMed ID: 1727959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.